News

New study reveals mechanisms for UVA1 phototherapy in scleroderma

A new study shows that UVA1 phototherapy — a treatment strategy that uses specific wavelengths of ultraviolet light — may work to reduce scarring in scleroderma by activating the aryl hydrocarbon receptor (AhR). This finding implies that activating the AhR protein may offer therapeutic benefits in the chronic autoimmune…

Risk of SSc Higher Following COVID-19, Study Finds

People who were infected with SARS-CoV-2, the virus that causes COVID-19, are at greater risk for developing autoimmune diseases, including scleroderma (SSc), according to a large study. The findings support recent evidence that viral infections may increase the likelihood of autoimmune conditions, although the mechanisms remain unknown. “It is…

Few Changes in Heart Health in SSc Patients Seen Over Time on MRIs

Monitoring the progression of subclinical heart disease with MRI scans suggested that abnormalities remain largely stable over time in people with systemic sclerosis (SSc), and such routine imaging may be of “minimal value”  to most patients, a small study reported. The study, “Subclinical Systemic Sclerosis Primary Heart Involvement by…

2 Inflammatory Biomarkers Linked to Greater Disease Activity in SSc

Elevations in two indices of body-wide inflammation are associated with greater disease activity in systemic sclerosis (SSc) patients, according to a recent study. The two inflammatory markers — called the platelet-to-lymphocyte ratio (PLR) and platelet-to-hemoglobin ratio (PHR) — were also associated with skin ulcers, and musculoskeletal and pulmonary…

EHP-101 Phase 2a Trial Cleared to Move to High Dose Groups

A Phase 2a clinical trial testing the oral cannabidiol-derived medication EHP-101 in people with diffuse cutaneous systemic sclerosis can proceed to the higher dose groups, the therapy candidate’s developer Emerald Health Pharmaceuticals (EHP) announced. The study is taking place in the U.S., including Puerto Rico, as well as…